Bleomycin Disaccharide Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The understanding of the molecular basis for tumor targeting by bleomycin is limited, hindering the selective delivery of probes and drugs to tumor cells, despite its innate tumor-specific behavior.
Innovation Solution
The carbohydrate moiety of bleomycin is sufficient for tumor cell targeting, as demonstrated by compounds derived from bleomycin's disaccharide moiety, which can be used to create pharmaceutical compositions and microbubble conjugates for imaging and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the complete bleomycin molecule is used for tumor targeting, then tumor targeting ability is achieved, but structural complexity increases
Solution Approach 1:
The patent extracts the disaccharide moiety from the complete bleomycin molecule and demonstrates that this isolated carbohydrate component retains sufficient tumor targeting ability. This extraction principle resolves the contradiction by removing unnecessary structural elements (the complex peptide and macrocyclic portions of bleomycin) while preserving the essential tumor-targeting function in the disaccharide unit.
Solution Approach 2:
The patent segments the bleomycin molecule into distinct functional domains, identifying the disaccharide moiety as the critical tumor-targeting segment. By focusing on this segmented portion rather than the entire molecule, the invention achieves tumor targeting with reduced structural complexity, allowing for simplified analogues and conjugates.
2Device complexity
If simplified disaccharide compounds are used, then molecular complexity is reduced, but understanding of tumor targeting mechanism is limited
Solution Approach 1:
The disaccharide compounds serve as intermediary structures that bridge the gap between simple sugars and complete bleomycin molecules. These intermediates maintain tumor targeting ability while being simpler than full bleomycin, enabling researchers to study targeting mechanisms without the complexity of the complete molecule, thus preventing information loss about the fundamental targeting mechanism.
Solution Approach 2:
The patent creates simplified copies of the tumor-targeting portion of bleomycin in the form of disaccharide analogues. These copies replicate the essential targeting function using simpler chemical structures, allowing mechanism studies to proceed with reduced molecular complexity while preserving the key informational aspects of tumor cell recognition and binding.
Data Source
AI summary
Tumors can be selectively targeted via compounds provided herein according to the formula, or a pharmaceutically acceptable salt thereof, wherein RA and RB are as defined herein. Tumors can be imaged or targeted for therapeutic treatment using compounds described herein where at least one RA or at least one RB group comprises a imaging agent, a therapeutic agent, or a member of a specific binding pair which can be associated with a secondary imaging agent, such as a microbubble for ultrasonic imaging.